Telo Genomics takes on costly $178K loan to cover operating costs
What's the deal? Telo GenomicsDealroom has a profile for this one. Try Dealroom →, a Toronto-based biotech developing diagnostic tests based on 3D analysis of telomeres, has secured a US$183.3K (roughly $178,000) term loan from BrightArc Capital Adminco 1 Inc. The non-dilutive, secured facility closed effective October 29, 2026, with an initial advance of $100,000 and the balance to follow.
What's the money for? Proceeds will fund general operating expenses. The loan is a demand non-revolving facility carrying 1.30% monthly interest — an annual rate of 15.6% — and is secured against the company's assets, including its Scientific Research and Experimental Development (SR&ED) tax credits.
Why now? The facility follows a US$1.02M convertible-debenture financing completed earlier this year at 15% annual interest, maturing December 15, 2026. In its March 2026 filing, Telo reported no revenue, ongoing operating cash outflows, and a working-capital deficit.
What's the endgame? Telo is building a telomere platform for liquid biopsies in oncology and neurological disease. Its lead application, Telo-MM, targets multiple myeloma, a blood cancer. The company says its technology is backed by more than 190 peer-reviewed publications and over 30 clinical studies involving more than 3,000 patients.
What could go wrong? The loan is due on the earlier of three business days after Telo receives its 2026 SR&ED claims or 12 months from advance — tying repayment directly to a tax refund. A minimum of three months of interest applies even if repaid early, and covenants require CRA payments to be routed to the lender's account.
The signal: For a pre-revenue biotech, short-term secured borrowing against future tax credits signals a focus on near-term liquidity rather than a major development milestone. It underlines how cash-strapped clinical-stage companies are leaning on costly, non-dilutive debt to bridge operations.
Read more: finance.yahoo.com
Image credit: Generated with Gemini
